top of page

Know Labs Enters into Research Agreement with Mayo Clinic

Updated: Sep 16, 2021

Seattle, WA. — July 21, 2020 — OTCQB: KNWN

Know Labs, Inc., an emerging leader in non-invasive medical diagnostics, announced today that it has entered into a Research Agreement with Mayo Clinic to test and validate its patented Bio-RFID™ platform technology. Know Labs plans to first deploy its Bio-RFID platform in its wearable UBAND™ as a non-invasive Continuous Glucose Monitor (CGM).

Phil Bosua, Know Labs CEO, stated, “We are very pleased to work with Mayo Clinic. They bring a world-renowned reputation in diagnostics. We look forward to working with them during this research project as we continue the development of our non-invasive UBAND CGM.”

See About Know Labs, Inc. and our Safe Harbor Statement for company and regulatory information.


Recent Posts

See All

Know Labs, Inc. Reports First Quarter FY2024 Results

SEATTLE – February 14, 2024 – Know Labs, Inc. (NYSE American: KNW), an emerging developer of non-invasive medical diagnostic technology, today reported financial results for the first quarter ended De

bottom of page